Acute Porphyria Drug Database

J07AN01 - Tuberculosis, Live Attenuated
Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the tuberculosis, live attenuated vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Live attenuated Mycobacterium bovis BCG (Bacillus Calmette-Guérin).
Therapeutic characteristics
The tuberculosis, live attenuated vaccine (BCG vaccine) is indicated for active immunization against against tuberculosis in individuals from the age of 6 weeks to 35 years. It is administered as a single intradermal injection.
Metabolism and pharmacokinetics
The BCG vaccine is not metabolized by the cytochrome P450 system.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. Norwegian medicines agency. Summary of Product Characteristics (SPC). BCG-vaksine SSI. #1869

Similar drugs
Explore alternative drugs in similar therapeutic classes J07A / J07AN or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙